Subjects were given GlaxoSmithKline human papillomavirus-16 / 18 AS04-adjuvanted cervical cancer vaccine ( and controls no vaccine ) at the first day of vaccination ( Day 0 ) , at 1 - and 6-month schedule and followed up until 7 months .
